公开(公告)号：KR20070100657A

公开(公告)日：2007-10-11

申请号：KR20070034003

申请日：2007-04-06

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FIBIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/22

CPC classification number: A61K31/04 ,  A61K31/165

Abstract: A pharmaceutical composition comprising agomelatine is provided to be used for treating generalized anxiety disorder and provide good acceptability profile to patients without side effects such as withdrawal symptoms occurring when being treated by using a conventional psychotropic drug stops. A pharmaceutical composition for treating generalized anxiety disorder comprises agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or a hydrate thereof, or a pharmaceutically acceptable acid or base addition salt thereof, and at least one pharmaceutically acceptable excipient thereof.

Abstract translation: 提供了含有阿莫西拉的药物组合物，用于治疗广泛性焦虑症，并且对于没有副作用的患者提供良好的可接受性，如通过使用常规精神药物停止治疗时出现的戒断症状。 一种用于治疗广泛性焦虑症的药物组合物包括阿米苏定或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺或其水合物或其药学上可接受的酸或碱加成盐，以及至少一种药学上可接受的盐 其可接受的赋形剂。

公开(公告)号：WO2008037888A3

公开(公告)日：2008-06-12

申请号：PCT/FR2007001557

申请日：2007-09-25

Applicant: SERVIER LAB ,  PEGLION JEAN-LOUIS ,  POITEVIN CHRISTOPHE ,  MILLAN MARK ,  BROCCO MAURICETTE

Inventor： PEGLION JEAN-LOUIS ,  POITEVIN CHRISTOPHE ,  MILLAN MARK ,  BROCCO MAURICETTE

IPC: C07D498/04 ,  A61K31/538 ,  A61P25/00

CPC classification number: C07D498/04

Abstract: Compounds of formula (I), of trans relative configuration: in which: X is an oxygen atom or an NR 2 group, Y is a group selected from -CH 2 -, -(CH 2 ) 2 - and -CH=CH-, R 1 and R 2 , which may be identical or different, are each a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof. Said compounds are useful as dopaminergic receptor ligands for the treatment of central nervous system diseases.

Abstract translation: 式（I）化合物：反式相对构型：其中：X为氧原子或NR 2 H 2基团，Y为选自-CH 2 - ， - （CH 2）2 - 和 - CH = CH-，R 1和R 2， 其可以相同或不同，分别为氢原子或选自烷基，环烷基和环烷基烷基的基团，外消旋形式或旋光异构体形式，以及其与药学上可接受的酸及其水合物的加成盐 。 所述化合物可用作治疗中枢神经系统疾病的多巴胺能受体配体。

公开(公告)号：JP2002356486A

公开(公告)日：2002-12-13

申请号：JP2002114443

申请日：2002-04-17

Applicant: SERVIER LAB

Inventor： LAVIELLE GILBERT ,  DUBUFFET THIERRY ,  MULLER OLIVIER ,  MILLAN MARK ,  DEKEYNE ANNE ,  BROCCO MAURICETTE

IPC: A61K31/519 ,  A61P1/14 ,  A61P15/10 ,  A61P15/12 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D471/00 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07D513/00 ,  C07D519/00

Abstract: PROBLEM TO BE SOLVED: To provide a medicine useful for treatment of depression, impulsive behavioral disorder, anxiety, schizophrenia, Parkinson's disease, dysgnosia, libido dysfunction, sexual dysfunction, appetite disorder and somnipathy due to α2 /5-HT2c antagonist characteristics possessed thereby. SOLUTION: This compound is represented by the formula (I) [wherein, R1 , R2 , R3 and R4 denote each hydrogen atom or the like; X denotes oxygen atom or the like; A denotes a linear or a branched (1-6C) alkylene chain; ring-B denotes an unsaturated nitrogen-containing heterocyclic ring; and R5 denotes a linear or a branched (1-6C) alkyl chain], its enantiomer and diastereoisomer and its addition salt with a pharmaceutically acceptable acid or base. The method for preparing the same and the pharmaceutical composition comprising the same are provided.

公开(公告)号：WO2006103342A8

公开(公告)日：2007-12-21

申请号：PCT/FR2006000673

申请日：2006-03-29

Applicant: SERVIER LAB ,  DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

IPC: C07D295/08 ,  A61K31/495 ,  A61P1/08 ,  A61P3/04 ,  A61P25/08 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30 ,  C07D213/40 ,  C07D295/12 ,  C07D295/14 ,  C07D333/20

CPC classification number: C07D213/40 ,  C07D295/096 ,  C07D295/135 ,  C07D295/155 ,  C07D333/20

Abstract: The invention concerns a compound of formula (I), wherein: R 3 represents a hydrogen atom; and R 1 and R 2 form together, with the carbon atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 form together, with the atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted; n represents 1 or 2; -X- represents a group selected among -(CH2) m -O-Ak-, -(CH 2 ) m -NR 4 -Ak-, - (CO)-NR 4 -Ak- and -(CH 2 ) m -NR 4 -(CO)-; m represents an integer between 1 and 6 inclusive; Ak represents an optionally substituted alkylene chain; and R 4 represents a hydrogen atom or an alkyl group; Ar represents an aryl or heteroaryl group; its optical isomers, as well as a pharmaceutically acceptable acid-addition salt thereof. The invention is applicable to medicines.

Abstract translation: 本发明涉及式（I）的化合物，其中：R 3代表氢原子; 和R SUB1和R SUB2与承载它们的碳原子一起形成苯环，萘环或喹啉环，每个所述环任选被取代，或R _{1表示氢原子，并且R 2和R 3与带有它们的原子一起形成苯环，萘环或喹啉环，每个 所述环任选被取代; n代表1或2; -X-表示选自 - （CH 2）m -O-Ak - ， - （CH 2 SUB）m -NR 4 - （CO） - ; m表示1和6之间的整数; Ak表示任选取代的亚烷基链; 并且R 4代表氢原子或烷基; Ar表示芳基或杂芳基; 其光学异构体，以及其药学上可接受的酸加成盐。 本发明适用于药物。}

公开(公告)号：WO2009022063A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000932

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C251/48 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C251/48

Abstract: Compounds of formula (I): in which: R1 is an alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and X is an N-OR2 group in which R2 is a hydrogen atom or an alkyl group. Medicaments.

Abstract translation: 式（I）化合物：其中：R 1是烷基，链烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，X是N-OR 2基团，其中R 2是氢原子或 烷基。 药物。

公开(公告)号：WO2009022066A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000935

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C233/18

Abstract: Compound of formula (I): Medicaments.

Abstract translation: 式（I）化合物：药物。

公开(公告)号：WO2006103342A2

公开(公告)日：2006-10-05

申请号：PCT/FR2006000673

申请日：2006-03-29

Applicant: SERVIER LAB ,  DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

IPC: C07D295/096 ,  A61K31/495 ,  A61P3/04 ,  A61P25/08 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30 ,  C07D213/40 ,  C07D295/135 ,  C07D295/155 ,  C07D333/20

CPC classification number: C07D213/40 ,  C07D295/096 ,  C07D295/135 ,  C07D295/155 ,  C07D333/20

Abstract: The invention concerns a compound of formula (I), wherein: R 3 represents a hydrogen atom; and R 1 and R 2 form together, with the carbon atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 form together, with the atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted; n represents 1 or 2; -X- represents a group selected among -(CH2) m -O-Ak-, -(CH 2 ) m -NR 4 -Ak-, - (CO)-NR 4 -Ak- and -(CH 2 ) m -NR 4 -(CO)-; m represents an integer between 1 and 6 inclusive; Ak represents an optionally substituted alkylene chain; and R 4 represents a hydrogen atom or an alkyl group; Ar represents an aryl or heteroaryl group; its optical isomers, as well as a pharmaceutically acceptable acid-addition salt thereof. The invention is applicable to medicines.

公开(公告)号：WO2009022065A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000934

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C233/18

Abstract: Compounds of formula (I): in which: R1 is an alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and R2 and R3 are a hydrogen atom or an alkyl group. Medicaments.

Abstract translation: 式（I）化合物：其中：R1是烷基，烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R2和R3是氢原子或烷基。 药物。

公开(公告)号：WO2009022064A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000933

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00 ,  C07C233/60

CPC classification number: C07C233/18 ,  C07C233/60 ,  C07C2601/02 ,  C07C2601/04

Abstract: Compounds of formula (I): in which: R1 is alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and R2 is a fluorine atom or an alkyl group substituted with one or more fluorine atoms. Medicaments.

Abstract translation: 式（I）的化合物：其中：R1是烷基，烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳烷基，杂芳基或杂芳基烷基，R2是氟原子或被一个或多个氟原子取代的烷基。 药物。

公开(公告)号：WO2006103342A9

公开(公告)日：2007-10-25

申请号：PCT/FR2006000673

申请日：2006-03-29

Applicant: SERVIER LAB ,  DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  GLOANEC PHILIPPE ,  MILLAN MARK ,  ORTUNO JEAN-CLAUDE ,  MANNOURY LA COUR CLOTILDE ,  GOBERT ALAIN

IPC: C07D295/08 ,  A61K31/495 ,  A61P1/08 ,  A61P3/04 ,  A61P25/08 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30 ,  C07D213/40 ,  C07D295/12 ,  C07D295/14 ,  C07D333/20

CPC classification number: C07D213/40 ,  C07D295/096 ,  C07D295/135 ,  C07D295/155 ,  C07D333/20

Abstract: The invention concerns a compound of formula (I), wherein: R 3 represents a hydrogen atom; and R 1 and R 2 form together, with the carbon atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 form together, with the atoms bearing them, a benzene, naphthalene or quinoline ring, each of said rings being optionally substituted; n represents 1 or 2; -X- represents a group selected among -(CH2) m -O-Ak-, -(CH 2 ) m -NR 4 -Ak-, - (CO)-NR 4 -Ak- and -(CH 2 ) m -NR 4 -(CO)-; m represents an integer between 1 and 6 inclusive; Ak represents an optionally substituted alkylene chain; and R 4 represents a hydrogen atom or an alkyl group; Ar represents an aryl or heteroaryl group; its optical isomers, as well as a pharmaceutically acceptable acid-addition salt thereof. The invention is applicable to medicines.

Abstract translation: 本发明涉及式（I）化合物，其中：R 3表示氢原子; 和R 1和R 2 2一起形成带有它们的碳原子，苯，萘或喹啉环，每个所述环任选被取代，或R _{1 表示氢原子，并且R 2和R 3和它们的原子一起形成苯，萘或喹啉环，每个 所述环任选被取代; n表示1或2; -X-表示选自以下的基团： - （CH 2）m -O-Ak-， - （CH 2 CH 2）m -N > - > - （ - ）（CO）-NR 4 -A - 和 - （CH 2 CH 2）m -NR 4 - （CO） - ; m表示1〜6的整数， Ak表示任选取代的亚烷基链; R 4表示氢原子或烷基; Ar表示芳基或杂芳基; 其光学异构体，以及其药学上可接受的酸加成盐。 本发明适用于药物。}